All In Biotech

Drug Trial Radar · NCT06958627

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 964 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

964

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Apr 30, 2025

Study completion Apr 30, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, randomized controlled clinical study to evaluate the effect of using intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment. Pyrotinib is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

Conditions

  • HER2 Positive Breast Cancer
  • Pyrotinib Treatment

Interventions

  • pyrotinibDrug

    Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. medication adherence at 1-yearTime frame: 1-year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.